Multiple Sclerosis Headlines

LATEST

Mononucleosis As Child, Teen May Increase Later Multiple Sclerosis Risk

Infectious mononucleosis during childhood, particularly during adolescence, appears to be a risk factor for subsequent diagnosis of MS.

T-Cell and Humoral Response to SARS-CoV-2 Vaccine in Patients With MS on Ocrelizumab

Researchers sought to determine the T-cell and antibody response to the SARS-CoV-2 vaccine in patients with multiple sclerosis treated with ocrelizumab, compared with healthy individuals.

Ublituximab BLA Submitted for Relapsing Forms of Multiple Sclerosis

Ublituximab is an investigational glycoengineered anti-CD20 monoclonal antibody.

MS Associated With Lower Early Survival in Patients With Colorectal Cancer

Using a retrospective matched cohort design, researchers determined whether overall and cancer-specific survival following a colorectal cancer diagnosis is lower in patients with multiple sclerosis (MS) than without MS.

Ocrelizumab Beneficial for Relapse Risk and Disability in Multiple Sclerosis

Researchers sought to evaluate the safety and treatment outcomes of ocrelizumab, a humanized anti-CD20 immunoglobulin G antibody, in patients with multiple sclerosis.

The Effect of MS Treatments on SARS-CoV-2 Vaccines and the Humoral Response

Researchers determined the impact of other disease-modifying treatments in multiple sclerosis and the effect of delaying anti-CD20 infusion on the humoral response to COVID-19 vaccines.

MRI Technique Shows Early Changes in Normal-Appearing White Matter in Pediatric MS

Using neurite orientation dispersion and density imaging, researchers investigated the presence of early microstructural damage and its link with physical disability and white matter lesion volume within tracts in pediatric patients with multiple sclerosis.

Probiotic Supplements Tied to Improved Outcomes in Relapsing Remitting MS

In a meta-analysis, researchers analyzed the effects of probiotics on disease progression, depression, general health, and anthropometric measures in patients with relapsing remitting multiple sclerosis.

Dimethyl Fumarate Shows Favorable Long-Term Benefit-Risk Profile in MS

A team of researchers assessed the long-term safety and efficacy of dimethyl fumarate for the treatment of patients with relapsing remitting multiple sclerosis for up to 13 years.

PHOMS Linked to Disease Duration, Higher Disability in Primary Progressive MS

This cross-sectional study assessed the frequency of peripapillary hyper-reflective ovoid masslike structures, a novel finding in retinal optical coherencetomography, in patients with early relapsing remitting MS and its link to disease duration in MS subtypes.